Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 6:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 82 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Remodulin Clear all

Conditions: Pulmonary Hypertension Due to Left Heart Disease
Interventions: Treprostinil Diolamine; Drug
Lead sponsor: Mardi Gomberg -Maitland MD, MSc; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Columbus, Ohio • Pittsburgh, Pennsylvania

Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Interventions: Placebo, Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer; Drug · Device
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 698 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 74
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 60 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Oral treprostinil; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 41
States / cities: Fresno, California • Los Angeles, California • San Juan Capistrano, California + 37 more

Conditions: Hypertension, Pulmonary
Interventions: treprostinil sodium; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 2
States / cities: La Jolla, California • San Diego, California

Conditions: Pulmonary Hypertension Associated With HFpEF
Interventions: Oral treprostinil; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 82
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Not listed
Lead sponsor: United Therapeutics; Industry
Eligibility: Not listed
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 51
States / cities: La Jolla, California • Los Angeles, California • Pasadena, California + 45 more

Conditions: Systemic Sclerosis
Interventions: treprostinil diethanolamine; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 3
States / cities: Baltimore, Maryland • Boston, Massachusetts • Ann Arbor, Michigan

Conditions: Pulmonary Arterial Hypertension, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Interventions: Treprostinil; Drug
Lead sponsor: Rajan Saggar; Other
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: PAH
Interventions: oral treprostinil; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 9
States / cities: Palo Alto, California • San Francisco, California • Aurora, Colorado + 6 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Treprostinil Diolamine, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 690 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Fresno, California + 33 more

Conditions: Raynaud's Disease, Raynaud Phenomena, Raynauds
Interventions: Oral treprostinil (UT-15C) sustained release tablets; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Interventions: Oral treprostinil, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 82
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more

Conditions: Hypertension, Pulmonary
Interventions: treprostinil inhalations, tadalafil; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 69 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Stanford, California • Chicago, Illinois

Conditions: Peripheral Vascular Disease
Interventions: Remodulin (treprostinil sodium) Injection; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 4
States / cities: Springfield, Illinois • Worcester, Massachusetts • Albany, New York + 1 more

Conditions: Systemic Sclerosis
Interventions: treprostinil diethanolamine; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 22
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 19 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Treprostinil Injectable Product, Riociguat Pill; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Pulmonary Hypertension, COPD
Interventions: Inhaled Treprostinil Therapy; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 30 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Aurora, Colorado • Jacksonville, Florida

Conditions: Pulmonary Hypertension
Interventions: UT-15C; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 9
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 5 more

Conditions: Pulmonary Hypertension
Interventions: treprostinil sodium; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Healthy
Interventions: UT-15C; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis
Interventions: Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer; Drug · Device
Lead sponsor: United Therapeutics; Industry
Eligibility: 40 Years and older
Enrollment: 1,850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 81
States / cities: Birmingham, Alabama • Franklin, Arizona • Phoenix, Arizona + 66 more

Conditions: Pulmonary Hypertension
Interventions: Inhaled treprostinil, Placebo inhalation solution; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 15
States / cities: Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 12 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Not listed
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Systemic Sclerosis, Calcinosis
Interventions: Oral treprostinil; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Palo Alto, California

Search by objective public record fields.

Telemonitoring to Treat Group 2 Pulmonary Hypertension

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

ADAPT - A Patient Registry of the Real-world Use of Orenitram®

Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction

Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF

Tyvaso Dosing and Titration Evaluation: TyTRATE Registry

Pharmacokinetics of Oral Treprostinil in Patients With Systemic Sclerosis

Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension

Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years

Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy

Open Label Treprostinil Raynaud's Study

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction

A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).

Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft

Open-Label Study of Oral Treprostinil in Digital Ulcers

Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH

Treatment of Pulmonary Hypertension Associated COPD With Inhaled Treprostinil-1

A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension

Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin

Three Times Daily Dosing of UT-15C

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)

Study Of Right Ventricular Performance In PAH Patients Treated With Rapid Dose Treprostinil (Remodulin)

Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis